50 percent. Half of everything you worked for on Mounjaro or Wegovy — gone within a year of stopping. That is not a worst-case scenario. That is what the clinical trials actually showed. And almost nobody tells you this before you stop.
If you are on a GLP-1 medication, thinking about stopping one, or trying to understand what your options really look like, this is the data you need to see.
What the Trials Actually Show
Let’s start with the numbers, because they matter.
The STEP-1 trial — the large-scale semaglutide study — looked specifically at what happened when patients discontinued the medication. Within 28 weeks of stopping — just seven months — participants had regained over 40 percent of their lost weight. Not some of it. Forty percent.
For Mounjaro (tirzepatide), the picture is even sharper. The SURMOUNT-4 trial showed that more than half of the weight loss rebounded within a year of stopping the medication. The rate of regain averaged approximately 0.8 kilograms per month — close to two pounds every single month after the last injection.
These are not fringe findings. This is the trial data. And most patients are never shown it before they make the decision to stop.
Why Your Body Fights Back — And Why Hunger Comes Back Stronger
Here is what I really want you to understand, because this is the part that gets left out of almost every conversation about stopping GLP-1s: this is not willpower. This is not failure. This is biology doing exactly what it was designed to do.
When you are on a GLP-1, the medication is doing real pharmacological work on your hunger hormones. It suppresses ghrelin — the hormone responsible for hunger signaling — and amplifies your fullness signals. You eat less because the medication is actively managing those signals. When you stop, those signals return. But here is what genuinely surprises most patients: hunger does not just return to baseline. In many patients, it rebounds higher than it was before they ever started.
Your body spent months in a calorie deficit. Its response is to compensate aggressively. That means stronger hunger cues than you experienced before treatment.
At the same time, your metabolism adapted during the weight loss period. Your resting metabolic rate declined. Your body became more efficient at running on fewer calories — and that adaptation does not disappear the moment the medication stops.
So you are left with a body that is burning fewer calories than before and hungrier than before — and the only thing managing both of those variables is gone. That is the mechanism behind the rebound, and it explains why it happens so quickly.
The Rebound Is Not Inevitable
This is the part I want to be clear about: the rebound is not inevitable. But preventing it requires building the protection in before you stop — not after.
1. Protect Your Muscle During Treatment
Research shows that many patients lose meaningful lean mass during GLP-1 treatment — not just fat. Every pound of muscle lost means your body burns fewer calories at rest, every single day. When you add that metabolic disadvantage to the hunger surge that follows discontinuation, you are starting from a much weaker position.
The patients who protect their lean mass during treatment — through consistent resistance training and adequate protein intake — have substantially better outcomes when they stop. This is not about aesthetics. It is about protecting your metabolic floor before the medication is removed.
2. How You Stop Matters as Much as the Decision to Stop
There is a significant difference between abrupt discontinuation and a structured taper.
A study presented at the 2024 European Congress on Obesity examined patients who tapered their semaglutide dose to zero over nine weeks with concurrent behavioral support around exercise and nutrition. After six months of being completely off the medication, their weight remained stable.
Compare that to the STEP-1 participants who stopped abruptly and lost 40 percent of their results in seven months. The taper protocol changed the trajectory entirely.
If you are planning to stop, that conversation with your provider should include a specific tapering schedule — not just a date to stop.
3. Monitor Your Labs After Stopping
The two numbers I watch most closely in patients who have discontinued a GLP-1 are fasting insulin and HOMA-IR — both measure insulin resistance. If those numbers begin trending upward after stopping, that is not a crisis, but it is a signal that your metabolic system needs more support. Catching it early is everything.
The Clinical Bottom Line
The GLP-1 rebound is real. The trial data is clear. But it is not something that simply happens to you — it happens to people who stop without a plan.
Build and protect your lean mass during treatment. If you stop, taper slowly and with clinical support. Monitor your metabolic labs in the months after. Your results are worth protecting, and the biology is navigable when you know what you are working with.
🔬 Free Download: 5 Metabolic Labs Your Doctor Isn’t Ordering
If you are on a GLP-1 or thinking about stopping one, these are the numbers you need to know. Download the free guide →
Dr. Natalie Howard is a Johns Hopkins-trained Doctor of Nursing Practice with advanced training in metabolic medicine and GLP-1 therapy. This content is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your medication.